{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011634","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.010770+00:00","generated_at":"2026-06-13T14:05:57.036476+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Mustang Bio extends asset sale deadline for Worcester facility to July 31, 2023","bullets":["Mustang Bio and uBriGene amended Asset Purchase Agreement to extend Outside Date from June 30 to July 31, 2023.","Extension provides additional time to obtain landlord approval for site lease transition.","Parties may mutually extend in 30-day increments if only condition is landlord consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011634","json":"https://secwatch.observer/filing/0001558370-23-011634.json","markdown":"https://secwatch.observer/filing/0001558370-23-011634.md","text":"https://secwatch.observer/filing/0001558370-23-011634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023011634/0001558370-23-011634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023011634/tmb-20230629x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:05:57.036476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f6caa42404f2ae3404e819d64598277b3355f1f","claim":"MUSTANG BIO, INC. amended Asset Purchase Agreement with uBriGene (Boston) Biosciences, Inc. valued at Extended Outside Date to July 31, 2023 (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023 the Company and uBriGene entered into an amendment to the Asset Purchase Agreement (the “ Amendment ”), to extend the Outside Date to July 31, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023011634/0001558370-23-011634-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"uBriGene (Boston) Biosciences, Inc."},{"label":"Value","value":"Extended Outside Date to July 31, 2023"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}